Cleary Gottlieb is representing Wockhardt Limited (Wockhardt), the global pharmaceutical and biotechnology major, in its agreement with the UK government to fill finish COVID-19 vaccines for the United Kingdom.
Manufacturing will be undertaken by C P Pharmaceuticals, a subsidiary of Wockhardt based in Wrexham, North Wales.
Under the terms of the agreement signed on July 31, 2020, the UK Department for Business, Energy & Industrial Strategy has reserved manufacturing capacity at Wockhardt’s facility to allow for the supply of designated vaccines to the UK government for the fight against COVID-19 in the United Kingdom.
Wockhardt expects to start delivering the first doses of vaccine later in 2020.
Wockhardt is listed on the Bombay Stock Exchange and the National Stock Exchange of India. In the United Kingdom, Wockhardt has been a longstanding supplier to the NHS and employs over 400 people at its high-tech manufacturing facility in Wrexham.